Alexandra Lisi on Scaling Manufacturing Efficiency to Support Cell Therapy

“One of the biggest challenges with cell therapy manufacturing is that it'svery expensive, and that expense translates to the cost to the patient or the reimbursement. So, by ultimately reducing the costs, reducing the process time, and ultimately the cost of production, not only are we making it easier on the different pharmaceutical companies to produce the products but also to ultimately reduce the cost to the patient and making these drugs more readily available to patients that desperately need them. It plays a small role but hopefully a significant one.”

ThermoFisher Scientific is focused on improving cell therapy manufacturing to help mitigate current challenges with costs to companies, payers, and patients, and access. The company has developed the CTS DynaCellect Magnetic Separation System in order to further this goal. The system is designed to enable precise cell isolation, cell activation, cell depletion and removal in conjunction with the Dynabeads system.

Benefits of the DynaCellect system were presented at the World Oncology Cell Therapy Congress (WOCTC) held April 25-26 in Boston, Massachusetts, by Alexandra Lisi, cell therapy field applications staff scientist, ThermoFisher Scientific. CGTLive spoke with Lisi to learn more about the DynaCellect system and how its characteristics could help support cell therapy manufacturing. She also stressed the importance of improving not only cell therapies themselves but also the supporting processes in manufacturing. As therapies become more efficient, the manufacturing behind them must also scale in efficiency as well as in cost efficiency.

Click here to read more coverage of WOCTC 2023.

REFERENCE

Lisi A. Automated and scalable closed-system platform for cell isolation and activation. Presented at: WOCTC; April 25-26; Boston, Massachusetts